Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    Should methotrexate be a first-line treatment for rheumatoid arthritis?
    William S. Wilke, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 207-208;

    The evidence is in: Methotrexate is safe and effective as a first-line treatment for rheumatoid arthritis for many patients.

  • You have access
    Diagnosing and treating plantar fasciitis: A conservative approach to plantar heel pain
    Christopher L. Tisdel, MD, Brian G. Donley, MD and James J. Sferra, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 231-235;

    A simple diagnostic and treatment strategy that emphasizes nonsurgical treatment for this frustrating condition.

  • You have access
    Angioedema: Frightening and frustrating
    William O. Wagner, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 203-205;

    The dramatic swelling of angioedema develops in minutes to hours. Often, no cause is apparent.

  • You have access
    Hypersensitivity syndrome to antiepileptic drugs: A review including new anticonvulsants
    Hajo M. Hamer, MD and Harold H. Morris, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 239-245;

    How to recognize this potentially fatal adverse reaction and choose a safe substitute drug.

  • You have access
    Should all diabetic patients take ACE inhibitors, even those without proteinuria?
    Byron J. Hoogwerf, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 208-209;

    To give ACE inhibitors to all diabetic patients would be premature, but these agents have clear indications in some patients.

  • You have access
    Management of perimenopause: Focus on alternative therapies
    Holly L. Thacker, MD and Delbert L. Booher, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 213-218;

    What unregulated over-the-counter products are your patients taking? What do these products do?

  • You have access
    Diagnosis and treatment of glucocorticoid-induced osteoporosis
    Dina Zaqqa, MD and Rebecca D. Jackson, MD
    Cleveland Clinic Journal of Medicine April 1999, 66 (4) 221-230;

    Nearly everyone loses bone mass when they take corticosteroids long-term. Physicians should take proactive steps to mitigate the problem.

  • You have access
    Thalidomide’s tightly controlled “comeback”
    Leonard H. Calabrese, DO
    Cleveland Clinic Journal of Medicine March 1999, 66 (3) 136-138;

    A drug that was banned 40 years ago because of its potential for causing serious birth defects has found new uses—with strict safeguards.

  • You have access
    Beta2-microglobulin amyloidosis in renal failure: Understanding this recently recognized condition
    Jonathan Kay, MD
    Cleveland Clinic Journal of Medicine March 1999, 66 (3) 145-147;

    Most long-term dialysis patients eventually acquire amyloid deposits, with resultant musculoskeletal problems. Yet, the condition was recognized only recently.

  • You have access
    Correction
    Cleveland Clinic Journal of Medicine March 1999, 66 (3) 155;

Pages

  • Previous
  • Next
  • 1
  • …
  • 430
  • 431
  • 432
  • 433
  • 434
  • 435
  • 436
  • 437
  • 438
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire